Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

The addictive properties of opioids and the lives shattered by their misuse and overprescription are heavily chronicled chapters of the early 21st century. For over 2 decades, scientists in academia ...

A new study adds to evidence which suggests treating breast cancer patients with sodium channel blockers could be a promising future treatment to prevent the spread of cancer during the gap between ...

Thomas Kleyman, MD, professor of medicine and chief of the renal-electrolyte division at the University of Pittsburgh Medical Center, is a senior author of the study. Sodium channels found outside the ...

Note: On January 30, 2025 the FDA approved the first-in-class non-opioid analgesic Journavx (suzetrigine) for the treatment of moderate to severe acute pain in adults. The novel drug reduces pain by ...

A novel, investigational NaV1.8 sodium channel blocker known as VX-548 reduced acute pain after abdominoplasty or bunionectomy at the highest dose, but not at lower doses, two phase II trials showed.

NavAb is a sodium channel cloned from a bacterium (Arcobacter butzleri) and has a well-known structure. Sumikama and Irie’s colleagues performed experiments with NavAb and three mutants. The ...

Channel Therapeutics Corporation, a clinical-stage biotechnology company focused on non-opioid pain treatments, expressed encouragement regarding Vertex Pharmaceuticals' recent Phase 2 data for ...

Considering taking supplements to treat Drug induced sodium channel blockade? Below is a list of common natural remedies used to treat or reduce the symptoms of Drug induced sodium channel blockade.

Editor’s Note (1/31/25): The U.S. Food and Drug Administration has approved the novel nonopioid medication suzetrigine for acute pain. That pain ranges from moderate to severe. The drug was tested in ...